

Benjamin G Vincent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3239239/publications.pdf>

Version: 2024-02-01

59
papers

8,456
citations

136885

32
h-index

143943

57
g-index

66
all docs

66
docs citations

66
times ranked

14120
citing authors

#	ARTICLE	IF	CITATIONS
1	Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. <i>Cancer Gene Therapy</i> , 2022, 29, 683-696.	2.2	4
2	Delivery strategies for cancer vaccines and immunoadjuvants. , 2022, , 359-408.		1
3	Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	43
4	B Cell Function in the Tumor Microenvironment. <i>Annual Review of Immunology</i> , 2022, 40, 169-193.	9.5	84
5	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
6	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	1.6	36
7	Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. <i>Clinical Cancer Research</i> , 2022, 28, 1690-1700.	3.2	7
8	Challenges and Gaps in Clinical Trial Genomic Data Management. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100193.	1.0	0
9	NeoSplice: a bioinformatics method for prediction of splice variant neoantigens. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	13
10	Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti-“PD-1 Therapy. <i>Cancer Immunology Research</i> , 2021, 9, 103-112.	1.6	10
11	Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge. <i>JCO Precision Oncology</i> , 2021, 5, 51-54.	1.5	7
12	Landscape and selection of vaccine epitopes in SARS-CoV-2. <i>Genome Medicine</i> , 2021, 13, 101.	3.6	30
13	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 591-599.	0.6	4
14	Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	43
15	Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1021.e1-1021.e5.	0.6	15
16	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 616-629.	2.6	41
17	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	84
18	Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis. <i>Journal of Autoimmunity</i> , 2020, 106, 102306.	3.0	21

#	ARTICLE	IF	CITATIONS
19	Heparin-induced thrombocytopenia associated with collection of hematopoietic progenitor cells by apheresis. <i>Journal of Clinical Apheresis</i> , 2020, 35, 59-61.	0.7	3
20	Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. <i>Translational Oncology</i> , 2020, 13, 100856.	1.7	9
21	Bronchoalveolar Tregs are associated with duration of mechanical ventilation in acute respiratory distress syndrome. <i>Journal of Translational Medicine</i> , 2020, 18, 427.	1.8	9
22	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and \pm PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4670-4681.	3.2	31
23	Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin Contraindication. <i>Clinical Cancer Research</i> , 2020, 26, 4260-4267.	3.2	35
24	Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 858.	1.8	16
25	B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 292-308.	1.6	62
26	Pathogenic Bhlhe40+ GM-CSF+ CD4+ T cells promote indirect alloantigen presentation in the GI tract during GVHD. <i>Blood</i> , 2020, 135, 568-581.	0.6	35
27	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	2.3	11
28	CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. <i>JCI Insight</i> , 2020, 5, .	2.3	52
29	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. <i>Journal of Cancer</i> , 2019, 10, 3344-3351.	1.2	19
30	Alternative tumour-specific antigens. <i>Nature Reviews Cancer</i> , 2019, 19, 465-478.	12.8	206
31	B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. <i>Cell</i> , 2019, 179, 1191-1206.e21.	13.5	291
32	Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. <i>Cancer Immunology Research</i> , 2019, 7, 1591-1604.	1.6	48
33	Prognostic value of B cells in cutaneous melanoma. <i>Genome Medicine</i> , 2019, 11, 36.	3.6	81
34	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	3.4	260
35	A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1706098.	11.1	130
36	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018, 173, 305-320.e10.	13.5	272

#	ARTICLE	IF	CITATIONS
37	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	6.6	3,706
38	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. <i>Cell Reports</i> , 2018, 23, 270-281.e3.	2.9	177
39	Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. <i>Blood Advances</i> , 2018, 2, 2052-2062.	2.5	24
40	Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. <i>Cancer Research</i> , 2018, 78, 3954-3968.	0.4	82
41	Combination Immunotherapy: A Dual Immunotherapy Nanoparticle Improves Tâ€Cell Activation and Cancer Immunotherapy (<i>Adv. Mater.</i> 25/2018). <i>Advanced Materials</i> , 2018, 30, 1870182.	11.1	4
42	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018, 23, 3392-3406.	2.9	324
43	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	128
44	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 4804-4820.	3.9	210
45	Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. <i>PLoS ONE</i> , 2018, 13, e0193832.	1.1	74
46	A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 250-262.	3.2	159
47	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. <i>Blood</i> , 2017, 130, 2131-2145.	0.6	37
48	HLAProfiler utilizes k-mer profiles to improve HLA calling accuracy for rare and common alleles in RNA-seq data. <i>Genome Medicine</i> , 2017, 9, 86.	3.6	41
49	Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. <i>JCI Insight</i> , 2017, 2, .	2.3	257
50	Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 1813-1825.	3.9	84
51	Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with Vâ€™™DJer. <i>Bioinformatics</i> , 2016, 32, 3729-3734.	1.8	59
52	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw144.	3.0	271
53	iWAS â€“ A novel approach to analyzing Next Generation Sequence data for immunology. <i>Cellular Immunology</i> , 2016, 299, 6-13.	1.4	8
54	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. <i>JCI Insight</i> , 2016, 1, e85902.	2.3	179

#	ARTICLE	IF	CITATIONS
55	Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3818-3829.	3.2	230
56	Deletion of naïve T cells recognizing the minor histocompatibility antigen HY with toxin-coupled peptide-MHC class I tetramers inhibits cognate CTL responses and alters immunodominance. <i>Transplant Immunology</i> , 2013, 29, 138-145.	0.6	10
57	One Is Better than Two: TCR Pairing and GVHD. <i>Science Translational Medicine</i> , 2013, 5, 188fs21.	5.8	2
58	The Use of Peptide-Major-Histocompatibility-Complex Multimers in Type 1 Diabetes Mellitus. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 515-524.	1.3	6
59	Toxin-Coupled MHC Class I Tetramers Can Specifically Ablate Autoreactive CD8+ T Cells and Delay Diabetes in Nonobese Diabetic Mice. <i>Journal of Immunology</i> , 2010, 184, 4196-4204.	0.4	55